JP2011513475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513475A5 JP2011513475A5 JP2010550258A JP2010550258A JP2011513475A5 JP 2011513475 A5 JP2011513475 A5 JP 2011513475A5 JP 2010550258 A JP2010550258 A JP 2010550258A JP 2010550258 A JP2010550258 A JP 2010550258A JP 2011513475 A5 JP2011513475 A5 JP 2011513475A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- pharmaceutically acceptable
- acceptable salt
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000002393 azetidinyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- -1 diazoniaspiro [4.5] decanyl Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000003566 oxetanyl group Chemical group 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010057430 Retinal injury Diseases 0.000 claims 2
- 206010038997 Retroviral infections Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000009759 skin aging Effects 0.000 claims 2
- 230000037380 skin damage Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0804755.7A GB0804755D0 (en) | 2008-03-14 | 2008-03-14 | Therapeutic compounds |
| PCT/GB2009/000661 WO2009112832A1 (en) | 2008-03-14 | 2009-03-13 | Tricyclic derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513475A JP2011513475A (ja) | 2011-04-28 |
| JP2011513475A5 true JP2011513475A5 (enExample) | 2012-03-22 |
Family
ID=39328122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550258A Pending JP2011513475A (ja) | 2008-03-14 | 2009-03-13 | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）の阻害剤としての三環式誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8362030B2 (enExample) |
| EP (1) | EP2265611A1 (enExample) |
| JP (1) | JP2011513475A (enExample) |
| AU (1) | AU2009224004A1 (enExample) |
| CA (1) | CA2716918C (enExample) |
| GB (1) | GB0804755D0 (enExample) |
| WO (1) | WO2009112832A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9216998B2 (en) * | 2012-02-15 | 2015-12-22 | Janssen Pharmaceutica Nv | Tricyclic indole derivatives useful endothelial lipase inhibitors |
| US9512486B2 (en) * | 2012-08-06 | 2016-12-06 | The Institute Of Cancer Research: Royal Cancer Hospital | Materials, methods, and systems for treating cancer |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| CN103936735B (zh) * | 2014-04-04 | 2015-11-11 | 沈阳工业大学 | 氮杂苯并薁衍生物及其制备方法和用途 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
| WO2018138050A1 (de) | 2017-01-26 | 2018-08-02 | Bayer Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| WO2019016110A1 (en) * | 2017-07-18 | 2019-01-24 | Lonza Ltd | PROCESS FOR THE PREPARATION OF 5-FLUORO-2-METHYL-3-NITROBENZOIC ACID AND METHYL ESTER |
| EP3619188B1 (en) * | 2017-07-18 | 2020-10-07 | Lonza Ltd | Method for preparation of 5-fluoro-2-methyl-3-nitrobenzoic acid and its methyl ester |
| WO2020156577A1 (zh) * | 2019-02-02 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 用于parp抑制剂的吲哚并七元酰肟类似物 |
| AU2020444056A1 (en) | 2020-04-21 | 2022-11-17 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
| EP4139298A4 (en) | 2020-04-21 | 2024-05-22 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| CN117105958B (zh) * | 2022-05-24 | 2025-08-29 | 科岭源生物科技(深圳)有限公司 | 一种制备5-ht3受体调节剂的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5958942A (en) * | 1994-07-15 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Tricyclic nitrogen ring compounds, their production and use |
| AU2935895A (en) | 1994-07-15 | 1996-02-16 | Takeda Chemical Industries Ltd. | Tricyclic compounds, their production and use |
| CA2214393A1 (en) | 1996-09-02 | 1998-03-02 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| AU5340298A (en) | 1996-12-27 | 1998-07-31 | Takeda Chemical Industries Ltd. | Stabilized tricyclic compound |
| JP2002515490A (ja) * | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | Ｐａｒｐ活性を抑制する縮合三環化合物 |
| TR200102005T2 (tr) | 1999-01-11 | 2001-12-21 | Agouron Pharmaceuticals,Inc. | Poli(adp-ribaz) polimerazların trisiklik inhibitörleri. |
| ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| EP1183259A2 (de) * | 1999-09-28 | 2002-03-06 | Basf Aktiengesellschaft | Azepinoindol-derivate, deren herstellung und anwendung |
| ATE372337T1 (de) | 2000-02-01 | 2007-09-15 | Abbott Gmbh & Co Kg | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
| FR2816942B1 (fr) | 2000-11-23 | 2003-05-09 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| EP1339402B1 (en) * | 2000-12-01 | 2010-08-25 | Eisai Inc. | Azaphenanthridone derivatives and their use as parp inhibitors |
| JP2005514412A (ja) * | 2001-12-27 | 2005-05-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 中枢神経系疾患を処置するために有用なアロイルピロールヘテロアリールおよびメタノール類 |
| BRPI0408996A (pt) | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
| PL1660095T3 (pl) | 2003-07-25 | 2010-07-30 | Cancer Research Tech Ltd | Tricykliczne inhibitory PARP |
| MXPA06009701A (es) | 2004-02-26 | 2007-03-26 | Inotek Pharmaceuticals Corp | Derivados de isoquinolina y metodos de uso de los mismos. |
| WO2006021801A1 (en) | 2004-08-26 | 2006-03-02 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| AU2007232297B2 (en) | 2006-04-03 | 2012-09-20 | Msd Italia S.R.L. | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors |
| EP2032140A1 (en) * | 2006-05-31 | 2009-03-11 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| GB0612971D0 (en) * | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0615809D0 (en) * | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
-
2008
- 2008-03-14 GB GBGB0804755.7A patent/GB0804755D0/en not_active Ceased
-
2009
- 2009-03-13 EP EP09719116A patent/EP2265611A1/en not_active Withdrawn
- 2009-03-13 JP JP2010550258A patent/JP2011513475A/ja active Pending
- 2009-03-13 US US12/922,270 patent/US8362030B2/en not_active Expired - Fee Related
- 2009-03-13 CA CA2716918A patent/CA2716918C/en not_active Expired - Fee Related
- 2009-03-13 AU AU2009224004A patent/AU2009224004A1/en not_active Abandoned
- 2009-03-13 WO PCT/GB2009/000661 patent/WO2009112832A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513475A5 (enExample) | ||
| JP2010536842A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| JP2009532452A5 (enExample) | ||
| US20220274934A1 (en) | Gcn2 and perk kinase inhibitors and methods of use thereof | |
| KR20140107574A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| CA2959757A1 (en) | Pyrazole derivatives as sgc stimulators | |
| OA12905A (en) | Combination therapy for hyperproliferative diseases. | |
| CA3082855A1 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists | |
| CN114026072A (zh) | 治疗特发性肺纤维化的方法 | |
| JP2018523689A5 (enExample) | ||
| EP4514790A1 (en) | Compounds for inhibiting kif18a | |
| EP3713923A1 (en) | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors | |
| JP2022025116A (ja) | 抗菌性化合物 | |
| EP4139292A1 (en) | 5-membered heteroaryl carboxamide compounds for treatment of hbv | |
| RU2015117647A (ru) | Новые производные пиразола | |
| KR20140107578A (ko) | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 | |
| JP2010500334A5 (enExample) | ||
| JP2011518843A5 (enExample) | ||
| EP3641756B1 (en) | Tricyclic compounds as cyp1 inhibitors | |
| US20210369724A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds | |
| JPWO2014069554A1 (ja) | キヌクリジンアミド誘導体及びその医薬用途 | |
| CA2482687A1 (en) | Treatment of mesothelioma | |
| TW200727904A (en) | Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine | |
| JP2013227299A5 (enExample) |